Literature DB >> 21719417

Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody.

Keiichi Sumida, Yoshifumi Ubara, Tatsuya Suwabe, Noriko Hayami, Rikako Hiramatsu, Eiko Hasegawa, Masayuki Yamanouchi, Junichi Hoshino, Naoki Sawa, Fumi Takemoto, Kenmei Takaichi, Kenichi Ohashi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719417     DOI: 10.1093/rheumatology/ker222

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  18 in total

1.  Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab.

Authors:  Kenchi Takenaka; Takehiko Ohba; Kozo Suhara; Yurie Sato; Kenji Nagasaka
Journal:  Clin Rheumatol       Date:  2013-12-20       Impact factor: 2.980

Review 2.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

3.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

4.  The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel
Journal:  J Autoimmun       Date:  2019-07-15       Impact factor: 7.094

5.  AP-VAS 2012 case report: a case of ANCA-negative pauci-immune crescentic glomerulonephritis associated with IL-6-producing adenosquamous cell carcinoma of the lung.

Authors:  Takashi Morikawa; Atsuhiro Yoshida; Shinya Kobayashi; Mikiko Shibata; Masahiro Hamada; Masatsugu Kishida; Chizuko Kitabayashi; Haruko Daga; Yoshio Konishi; Koji Takeda; Masahito Imanishi
Journal:  CEN Case Rep       Date:  2013-03-14

6.  Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Shunsuke Yamada; Akihiro Tsuchimoto; Yoshiki Kaizu; Masatomo Taniguchi; Kosuke Masutani; Hiroshi Tsukamoto; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-29

7.  Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN.

Authors:  Carole Henique; Guillaume Bollee; Olivia Lenoir; Neeraj Dhaun; Marine Camus; Anna Chipont; Kathleen Flosseau; Chantal Mandet; Masayuki Yamamoto; Alexandre Karras; Eric Thervet; Patrick Bruneval; Dominique Nochy; Laurent Mesnard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 8.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

Review 9.  Management of Small Vessel Vasculitides.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Giacomo Emmi; Maria Grazia Anelli; Giovanni Lapadula; Florenzo Iannone; Luca Cantarini
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

10.  Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.

Authors:  Daichi Fukaya; Tsutomu Inoue; Yuta Kogure; Hiroshi Kajiyama; Keisuke Ishizawa; Takeru Seto; Hajime Hasegawa; Toshihide Mimura; Hirokazu Okada
Journal:  CEN Case Rep       Date:  2020-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.